Immuneering (IMRX) Operating Leases (2020 - 2024)
Historic Operating Leases for Immuneering (IMRX) over the last 5 years, with Q3 2024 value amounting to $4.2 million.
- Immuneering's Operating Leases fell 663.99% to $4.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $4.2 million, marking a year-over-year decrease of 663.99%. This contributed to the annual value of $4.2 million for FY2023, which is 672.44% down from last year.
- Per Immuneering's latest filing, its Operating Leases stood at $4.2 million for Q3 2024, which was down 663.99% from $4.3 million recorded in Q2 2024.
- Over the past 5 years, Immuneering's Operating Leases peaked at $5.1 million during Q4 2021, and registered a low of $481965.0 during Q3 2021.
- In the last 5 years, Immuneering's Operating Leases had a median value of $4.5 million in 2022 and averaged $3.7 million.
- The largest annual percentage gain for Immuneering's Operating Leases in the last 5 years was 84252.76% (2022), contrasted with its biggest fall of 1233.45% (2022).
- Immuneering's Operating Leases (Quarter) stood at $544767.0 in 2020, then soared by 834.51% to $5.1 million in 2021, then dropped by 12.33% to $4.5 million in 2022, then dropped by 6.72% to $4.2 million in 2023, then grew by 1.88% to $4.2 million in 2024.
- Its Operating Leases stands at $4.2 million for Q3 2024, versus $4.3 million for Q2 2024 and $4.4 million for Q1 2024.